XTLB
X.T.L. Biopharmaceuticals Ltd (XTLB)
Healthcare • NASDAQ • $2.54-4.87%
- Symbol
- XTLB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.54
- Daily Change
- -4.87%
- Market Cap
- $6.01M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $10.28
- 52W Low
- $2.12
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.71
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Company websiteResearch XTLB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.